Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Molecular Psychiatry|June 17, 2021
In vivo evidence of lower synaptic vesicle density in schizophreniaRajiv Radhakrishnan, Patrick D Skosnik, Mohini Ranganathan, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 25, 2012
Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot studyDeepak C D'Souza, Rajiv Radhakrishnan, Edward Perry, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 24, 2012
Glycine treatment of the risk syndrome for psychosis: report of two pilot studiesScott W Woods, Barbara C Walsh, Keith A Hawkins, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2020
A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressantsChadi G Abdallah, Kyung-Heup Ahn, Lynnette A Averill, et al.
Psychopharmacology|February 1, 2005
Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamineHyun-Sang Cho, Deepak C D'Souza, Ralitza Gueorguieva, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 17, 2013
The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivityNaomi R Driesen, Gregory McCarthy, Zubin Bhagwagar, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2025
Network-based Molecular Constraints on in vivo Synaptic Density Alterations in SchizophreniaSidhant Chopra, Patrick D Worhunsky, Mika Naganawa, et al.
The Journal of Clinical Psychiatry|June 13, 2012
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trialRichard S E Keefe, Sophia Vinogradov, Alice Medalia, et al.
Molecular Psychiatry|June 25, 2026
Widespread synaptic density loss in schizophrenia follows molecular and network architectureSidhant Chopra, Patrick D Worhunsky, Mika Naganawa, et al.
Biological Psychiatry|April 17, 2026
Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers - A "Disordinal" EffectMarco Cecchi, Jason Johannesen, Brandon Farley, et al.
Pageof 4